Crystec’s Chief Scientist contributes to the publication of distinguished work by SIMM, from Shanghai Synchrotron studies, which provides new insights into the development of inhaled medicines
TIANJIN, CHINA: April 6, 2021.
The recent publication of research conducted by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, in collaboration with scientists across China and the University of Bradford, UK, where Crystec’s Chief Scientist, Peter York, serves as Emeritus Professor, provides new and valuable insights into pre-clinical inhaled drug development. The study demonstrates the novel use of Synchrotron imaging to bridge the gap between in vitro and in vivo evaluation, providing a correlation between particle properties and lung deposition.
Crystec have a long-standing and highly valued partnership with SIMM, a leading pharmaceutical research institute which is recognized worldwide for its outstanding research. Crystec’s own collaborations with SIMM have included work to increase the bioavailability and stability of the artemisinin (originally a natural compound from traditional Chinese medicine), as well as a prestigious Newton Fund programme to enable the development of novel inhaled therapeutics to address the impact of COPD in China.
“This recently published data, generated using the Shanghai Synchrotron facility, is of particular importance to Crystec as it links to our vision for developing optimised inhaled therapies to address unmet clinical need in respiratory and systemic diseases. Through our collaboration with SIMM, Crystec have had the privilege of excellent research support, including the use of world-class scientific infrastructure and resource. We are immensely proud of the valuable research reported by our partners and are committed to continued collaboration in the pursuit of designing and providing efficacious medicines which improve patient care.” said Prof. Peter York.
Prof. Jiwen Zhang, SIMM, said: “Since 2009, Prof. Peter York has been collaborating with us to develop and promote the new research area of Structure Pharmaceutics, in which the Shanghai Synchrotron has been utilised to analyse the internal structure of particles accurately and quantitatively. The study in this paper illustrated the distribution of inhaled particles in the lungs and demonstrated the multi-scale structure and spatial distribution relationship between particles and the lungs, providing important guidance to the design of drug particles and powder in the preparation of dry powder inhalation products.”
Through an ongoing commitment to collaborations with strategic partners in China, Crystec have access to some of the best scientific facilities in the world, including the highly sought-after Shanghai Synchrotron and Micro-Optical Sectioning Tomography, the value of which is exemplified by this recent publication.
For further information, please contact Emily Bevis, Business Development Manager
emily.bevis@crystecpharma.com, +44 1274 235592
About CrystecPharma
CrystecPharma is a pharmaceutical crystal and particle engineering company, applying proprietary mSAS® supercritical fluid technology to improve the performance of medicines. The company has a strong research and development base, in both the UK and China. Crystec supports pharmaceutical companies to optimise the development of their own products, typically through improving bioavailability, stability or changing routes of administration. Use of the mSAS® platform can greatly shorten development times, generating high quality, readily-scalable products. The company also applies the strength of its technology to develop its own unique supergeneric products. Crystec is a young, dynamic company, with a passion for ensuring that strong science benefits human health.
For more information, please visit www.crystecpharma.com.
References
To keep up to date with the latest news from Crystec, please follow us on LinkedIn.